Kovina A P, Petrova N V, Razin S V, Kantidze O L
Institute of Gene Biology Russian Academy of Sciences, Moscow, 119334 Russia.
Acta Naturae. 2020 Oct-Dec;12(4):5-14. doi: 10.32607/actanaturae.11060.
Recent studies have significantly expanded our understanding of the mechanisms of L-ascorbic acid (ASC, vitamin C) action, leading to the emergence of several hypotheses that validate the possibility of using ASC in clinical practice. ASC may be considered an epigenetic drug capable of reducing aberrant DNA and histone hypermethylation, which could be helpful in the treatment of some cancers and neurodegenerative diseases. The clinical potency of ASC is also associated with regenerative medicine; in particular with the production of iPSCs. The effect of ASC on somatic cell reprogramming is most convincingly explained by a combined enhancement of the activity of the enzymes involved in the active demethylation of DNA and histones. This review describes how ASC can affect the epigenetic status of a cell and how it can be used in anticancer therapy and stem cell reprogramming.
最近的研究显著扩展了我们对L-抗坏血酸（ASC，维生素C）作用机制的理解，从而产生了几种假说，证实了在临床实践中使用ASC的可能性。ASC可被视为一种表观遗传药物，能够减少异常的DNA和组蛋白高甲基化，这可能有助于治疗某些癌症和神经退行性疾病。ASC的临床效力还与再生医学有关；特别是与诱导多能干细胞（iPSC）的产生有关。ASC对体细胞重编程的影响最令人信服的解释是，它能联合增强参与DNA和组蛋白活性去甲基化的酶的活性。本综述描述了ASC如何影响细胞的表观遗传状态，以及它如何用于抗癌治疗和干细胞重编程。
